Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$12.17 USD
+0.08 (0.66%)
Updated Sep 23, 2024 03:59 PM ET
2-Buy of 5 2
B Value C Growth C Momentum B VGM
Balance Sheet
Fiscal Year End for Astellas Pharma Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,414 | 2,982 | 2,765 | 2,988 | 3,008 |
Receivables | 3,629 | 3,352 | 3,312 | 3,218 | 3,400 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1,647 | 1,311 | 1,255 | 1,478 | 1,385 |
Other Current Assets | 222 | 250 | 238 | 177 | 166 |
Total Current Assets | 7,912 | 7,894 | 7,568 | 7,861 | 7,959 |
Net Property & Equipment | 1,945 | 2,154 | 2,205 | 2,384 | 2,464 |
Investments & Advances | 824 | 831 | 835 | 928 | 724 |
Other Non-Current Assets | 133 | 182 | 244 | 306 | 312 |
Deferred Charges | 302 | 633 | 593 | 488 | 485 |
Intangibles | 12,401 | 6,698 | 7,594 | 8,428 | 9,229 |
Deposits & Other Assets | 123 | 77 | 78 | 89 | 93 |
Total Assets | 23,640 | 18,470 | 19,118 | 20,483 | 21,268 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1,226 | 1,054 | 1,072 | 1,124 | 1,578 |
Current Portion Long-Term Debt | 3,128 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 646 | 1,354 | 1,516 | 1,335 | 3,172 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 255 | 39 | 265 | 76 | 37 |
Other Current Liabilities | 3,259 | 3,011 | 2,782 | 2,802 | 2,542 |
Total Current Liabilities | 8,515 | 5,459 | 5,635 | 5,337 | 7,328 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 340 | 45 | 48 | 164 | 254 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2,965 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1,250 | 1,628 | 1,467 | 2,495 | 1,859 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 13,070 | 7,132 | 7,148 | 7,996 | 9,440 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 682 | 774 | 844 | 928 | 945 |
Capital Surplus | 1,219 | 1,363 | 1,471 | 1,602 | 1,628 |
Retained Earnings | 5,360 | 6,828 | 7,740 | 8,588 | 8,311 |
Other Equity | 3,532 | 2,561 | 2,029 | 1,508 | 1,009 |
Treasury Stock | 224 | 189 | 114 | 139 | 66 |
Total Shareholder's Equity | 10,569 | 11,338 | 11,970 | 12,488 | 11,827 |
Total Liabilities & Shareholder's Equity | 23,640 | 18,470 | 19,118 | 20,483 | 21,268 |
Total Common Equity | 10,569 | 11,338 | 11,970 | 12,488 | 11,827 |
Shares Outstanding | 1,809.60 | 1,809.60 | 1,835.80 | 1,861.70 | 1,888.80 |
Book Value Per Share | 5.84 | 6.27 | 6.52 | 6.71 | 6.26 |
Fiscal Year End for Astellas Pharma Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2,167 | 2,414 | 1,941 | 2,509 | 4,401 |
Receivables | 3,840 | 3,629 | 3,440 | 3,482 | 3,484 |
Notes Receivable | 0 | 0 | NA | NA | 0 |
Inventories | 1,639 | 1,647 | 1,537 | 1,474 | 1,462 |
Other Current Assets | 294 | 222 | 223 | 241 | 272 |
Total Current Assets | 7,940 | 7,912 | 7,141 | 7,706 | 9,617 |
Net Property & Equipment | 1,982 | 1,945 | 1,965 | 2,046 | 2,123 |
Investments & Advances | 851 | 824 | 797 | 819 | 807 |
Other Non-Current Assets | 141 | 133 | 142 | 150 | 168 |
Deferred Charges | 347 | 302 | 290 | 306 | 735 |
Intangibles | 12,460 | 12,401 | 12,514 | 13,361 | 6,907 |
Deposits & Other Assets | 187 | 123 | 58 | 60 | 70 |
Total Assets | 23,907 | 23,640 | 22,907 | 24,447 | 20,425 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | 0 |
Accounts Payable | 1,108 | 1,226 | 1,023 | 1,016 | 1,011 |
Current Portion Long-Term Debt | 3,517 | 3,128 | 2,769 | 2,874 | 2,256 |
Current Portion Capital Leases | 667 | 646 | 684 | 681 | 730 |
Accrued Expenses | 0 | 0 | NA | NA | 0 |
Income Taxes Payable | 190 | 255 | 237 | 216 | 119 |
Other Current Liabilities | 3,310 | 3,259 | 3,132 | 3,232 | 3,123 |
Total Current Liabilities | 8,792 | 8,515 | 7,845 | 8,020 | 7,238 |
Mortgages | 0 | 0 | NA | NA | 0 |
Deferred Taxes/Income | 288 | 340 | 476 | 639 | 48 |
Convertible Debt | 0 | 0 | NA | NA | 0 |
Long-Term Debt | 2,836 | 2,965 | 3,154 | 3,264 | 365 |
Non-Current Capital Leases | 0 | 0 | NA | NA | 0 |
Other Non-Current Liabilities | 1,262 | 1,210 | 1,212 | 1,252 | |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | 0 |
Total Liabilities | 13,178 | 13,070 | 12,685 | 13,135 | 8,903 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | 0 |
Common Stock (Par) | 659 | 682 | 700 | 711 | 752 |
Capital Surplus | 1,169 | 1,219 | 1,244 | 1,257 | 1,319 |
Retained Earnings | 5,016 | 5,360 | 5,703 | 6,103 | 6,457 |
Other Equity | 4,132 | 3,532 | 2,807 | 3,478 | 3,246 |
Treasury Stock | 247 | 224 | 232 | 237 | 252 |
Total Shareholder's Equity | 10,729 | 10,569 | 10,222 | 11,311 | 11,522 |
Total Liabilities & Shareholder's Equity | 23,907 | 23,640 | 22,907 | 24,447 | 20,425 |
Total Common Equity | 10,729 | 10,569 | 110,221 | 111,310 | 11,522 |
Shares Outstanding | 1,809.60 | 1,809.60 | 1,809.60 | 1,809.60 | 1,809.60 |
Book Value Per Share | 5.93 | 5.84 | 60.91 | 61.51 | 6.37 |